Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Figure 1

Overall survival with a daily dose of lenvatinib ≤10 mg and ≥14 mg (maintenance dose showed a statistically significant effect on survival).